ECSP14017562A - Formulación de anticuerpo il-17 - Google Patents

Formulación de anticuerpo il-17

Info

Publication number
ECSP14017562A
ECSP14017562A ECIEPI201417562A ECPI201417562A ECSP14017562A EC SP14017562 A ECSP14017562 A EC SP14017562A EC IEPI201417562 A ECIEPI201417562 A EC IEPI201417562A EC PI201417562 A ECPI201417562 A EC PI201417562A EC SP14017562 A ECSP14017562 A EC SP14017562A
Authority
EC
Ecuador
Prior art keywords
antibody formulation
pharmaceutical formulations
antibody
psoriasis
antibodies
Prior art date
Application number
ECIEPI201417562A
Other languages
English (en)
Inventor
Patrick Donovan
Aaron Markham
Barbara Williams
Vincent John Corvari
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP14017562A publication Critical patent/ECSP14017562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a formulaciones farmacéuticas para anticuerpos anti-IL-17. Estas formulaciones farmacéuticas de anticuerpo anti-IL-17 pueden ser usadas para tratar artritis reumatoide, psoriasis, espondilitis anquilosante, artritis psoriática o mieloma múltiple.
ECIEPI201417562A 2012-03-07 2014-09-05 Formulación de anticuerpo il-17 ECSP14017562A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607671P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
ECSP14017562A true ECSP14017562A (es) 2015-09-30

Family

ID=47892018

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201417562A ECSP14017562A (es) 2012-03-07 2014-09-05 Formulación de anticuerpo il-17

Country Status (35)

Country Link
US (3) US9376491B2 (es)
EP (2) EP3156073A1 (es)
JP (1) JP6117252B2 (es)
KR (1) KR101653082B1 (es)
CN (1) CN104159612B (es)
AU (1) AU2013230490B2 (es)
BR (1) BR112014021308B1 (es)
CA (1) CA2866128C (es)
CL (1) CL2014002204A1 (es)
CY (1) CY1118393T1 (es)
DK (1) DK2822590T3 (es)
EA (1) EA030742B1 (es)
EC (1) ECSP14017562A (es)
ES (1) ES2610707T3 (es)
HK (1) HK1199844A1 (es)
HR (1) HRP20161604T1 (es)
HU (1) HUE031290T2 (es)
IL (1) IL234053B (es)
LT (1) LT2822590T (es)
MA (1) MA37317B1 (es)
ME (1) ME02565B (es)
MX (1) MX362191B (es)
MY (1) MY167233A (es)
NZ (1) NZ627648A (es)
PE (1) PE20142275A1 (es)
PH (1) PH12014501985B1 (es)
PL (1) PL2822590T3 (es)
PT (1) PT2822590T (es)
RS (1) RS55417B1 (es)
SG (1) SG11201404491XA (es)
SI (1) SI2822590T1 (es)
TN (1) TN2014000341A1 (es)
UA (1) UA114620C2 (es)
WO (1) WO2013134052A1 (es)
ZA (1) ZA201405654B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2019027828A1 (en) * 2017-08-04 2019-02-07 Eli Lilly And Company DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
JP7212675B2 (ja) 2017-08-23 2023-01-25 イーライ リリー アンド カンパニー 性器乾癬の治療
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
MX2021009851A (es) * 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
EP4268803A1 (en) * 2020-12-22 2023-11-01 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2481753T3 (pl) * 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
JP5410985B2 (ja) * 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤
MY182680A (en) * 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens

Also Published As

Publication number Publication date
SI2822590T1 (sl) 2017-01-31
MX2014010710A (es) 2015-04-14
CY1118393T1 (el) 2017-06-28
JP6117252B2 (ja) 2017-04-19
US20180057584A1 (en) 2018-03-01
KR101653082B1 (ko) 2016-08-31
BR112014021308A2 (pt) 2017-07-04
EA030742B1 (ru) 2018-09-28
US10472416B2 (en) 2019-11-12
US9845353B2 (en) 2017-12-19
PE20142275A1 (es) 2015-01-08
HRP20161604T1 (hr) 2016-12-30
HUE031290T2 (hu) 2017-06-28
WO2013134052A1 (en) 2013-09-12
AU2013230490A1 (en) 2014-08-14
EA201491471A1 (ru) 2014-12-30
TN2014000341A1 (en) 2015-12-21
CL2014002204A1 (es) 2015-01-30
ME02565B (me) 2017-02-20
EP2822590B1 (en) 2016-10-26
SG11201404491XA (en) 2014-09-26
KR20140120938A (ko) 2014-10-14
US20150010573A1 (en) 2015-01-08
HK1199844A1 (zh) 2015-07-24
BR112014021308B1 (pt) 2022-08-30
EP2822590A1 (en) 2015-01-14
ZA201405654B (en) 2016-05-25
PH12014501985A1 (en) 2014-11-24
MX362191B (es) 2019-01-08
DK2822590T3 (en) 2017-01-23
US9376491B2 (en) 2016-06-28
NZ627648A (en) 2016-10-28
MY167233A (en) 2018-08-14
US20160280781A1 (en) 2016-09-29
CA2866128C (en) 2017-02-28
IL234053A0 (en) 2014-09-30
PH12014501985B1 (en) 2014-11-24
MA37317A1 (fr) 2016-03-31
AU2013230490B2 (en) 2017-04-13
CA2866128A1 (en) 2013-09-12
UA114620C2 (uk) 2017-07-10
PL2822590T3 (pl) 2017-06-30
CN104159612A (zh) 2014-11-19
JP2015510882A (ja) 2015-04-13
ES2610707T3 (es) 2017-05-03
LT2822590T (lt) 2017-01-25
IL234053B (en) 2018-06-28
EP3156073A1 (en) 2017-04-19
RS55417B1 (sr) 2017-04-28
PT2822590T (pt) 2016-12-15
MA37317B1 (fr) 2016-10-31
CN104159612B (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
ECSP14017562A (es) Formulación de anticuerpo il-17
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
BRPI0807710A8 (pt) Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
CL2014001123A1 (es) Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene.
PE20150002A1 (es) Anticuerpos anti-fcrn
CR20150153A (es) Tratamiento para artitris reumatoide
AR094872A1 (es) Anticuerpos anti-tnf-anti-il-17 biespecíficos
CO7111294A2 (es) Anticuerpo anti-fgfr2
MX2016006101A (es) Agente ligante de la il-17a y usos del mismo.
EA201590412A1 (ru) Композиции антител и их применения
FR3012725B1 (fr) Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CL2021002815A1 (es) Usos de anticuerpos anti-il-17a/f (divisional 2018-01135)
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
EP3560956A3 (en) Methods of treating inflammatory diseases
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
TN2013000145A1 (en) Methods of treating psoriasis using il-17 antagonists
TH159903A (th) สูตรผสมแอนติบอดี il-17
UA112301C2 (uk) Антитіло до il-23